Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INM 
InMed Pharmaceuticals Inc (INM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: INM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.77% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.08M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) - | Beta 0.28 | 52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 |
52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -168.9% | Operating Margin (TTM) -167.67% |
Management Effectiveness
Return on Assets (TTM) -44.64% | Return on Equity (TTM) -91.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297344 | Price to Sales(TTM) 0.83 |
Enterprise Value 297344 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 1 | Shares Outstanding 1207190 | Shares Floating 1205387 |
Shares Outstanding 1207190 | Shares Floating 1205387 | ||
Percent Insiders 1.45 | Percent Institutions 10.18 |
Upturn AI SWOT
InMed Pharmaceuticals Inc
Company Overview
History and Background
InMed Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based therapies. Founded in 2014, InMed has focused on developing novel therapies for diseases with high unmet medical needs.
Core Business Areas
- Drug Discovery and Development: Focuses on developing novel cannabinoid-based therapies for various diseases, including dermatological and ocular diseases.
- Intellectual Property Management: Management and growth of the company's patent portfolio related to cannabinoid therapeutics.
Leadership and Structure
The leadership team includes executive officers responsible for R&D, finance, and commercial strategy. The company operates with a structure typical of biotech firms, emphasizing research and development.
Top Products and Market Share
Key Offerings
- INM-755 (cannabinoid cream): A cannabinoid cream in development for the treatment of epidermolysis bullosa (EB). Competitors include Castle Creek Biosciences (privately held) and Phoenix Tissue Repair (privately held). Market share data is not yet applicable as it is in development.
- INM-901 (cannabinoid eye drop): A cannabinoid eye drop in development for the treatment of glaucoma. Competitors include Aerie Pharmaceuticals (acquired by Alcon) and Allergan (acquired by AbbVie). Market share data is not yet applicable as it is in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the cannabinoid-based therapeutics segment, is experiencing growth due to increasing acceptance of medical cannabis and ongoing research into its therapeutic potential. Regulatory hurdles and clinical trial successes remain key factors.
Positioning
InMed is positioned as a specialty biopharmaceutical company focused on developing cannabinoid-based therapies for specific niche markets with high unmet medical needs. Its competitive advantage lies in its proprietary cannabinoid library and drug delivery technologies.
Total Addressable Market (TAM)
The total addressable market for cannabinoid-based therapeutics is expected to reach billions of dollars in the coming years. InMed is targeting specific indications like epidermolysis bullosa and glaucoma, positioning it to capture a portion of this TAM upon successful product development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary cannabinoid library
- Novel drug delivery technologies
- Focus on unmet medical needs
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Regulatory uncertainty
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory changes favoring cannabinoid therapies
- Successful clinical trial results
Threats
- Competition from established pharmaceutical companies
- Negative clinical trial results
- Unfavorable regulatory changes
- Difficulty securing funding
Competitors and Market Share
Key Competitors
- ABBV
- ALC
Competitive Landscape
InMed faces competition from established pharmaceutical companies with greater resources and established products. Its advantage lies in its focus on cannabinoid-based therapies and niche indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily marked by advancements in its clinical programs and the expansion of its intellectual property portfolio.
Future Projections: Future growth is contingent upon successful clinical trial results, regulatory approvals, and commercialization of its cannabinoid-based therapies. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing its INM-755 and INM-901 programs through clinical trials and exploring potential partnerships.
Summary
InMed Pharmaceuticals Inc. is a high-risk, high-reward biopharmaceutical company focused on cannabinoid-based therapies. The company's success hinges on positive clinical trial outcomes and securing partnerships for commercialization. While its innovative approach and proprietary technology offer potential advantages, it faces significant competition and regulatory hurdles. InMed needs to focus on strategic partnerships and financial management to succeed in the competitive biotech landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-11-12 | President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.inmedpharma.com |
Full time employees 13 | Website https://www.inmedpharma.com | ||
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.